Paul Ruff to Colorectal Neoplasms
This is a "connection" page, showing publications Paul Ruff has written about Colorectal Neoplasms.
Connection Strength
3,550
-
It's contrary - comorbidity does not affect survival of South Africans with colorectal cancer: An analysis from the Colorectal Cancer in South Africa cohort. S Afr Med J. 2020 Apr 29; 110(5):382-388.
Score: 0,661
-
Colorectal Cancer (CRC) treatment and associated costs in the public sector compared to the private sector in Johannesburg, South Africa. BMC Health Serv Res. 2020 Apr 07; 20(1):290.
Score: 0,658
-
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol. 2018 01; 9(1):32-39.
Score: 0,547
-
Burn-injured patients - the preferably unheard. S Afr J Surg. 2022 Dec; 60(4):229-234.
Score: 0,198
-
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biol Ther. 2020 10 02; 21(10):891-898.
Score: 0,170
-
Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression. Microrna. 2019; 8(1):68-75.
Score: 0,151
-
Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. Clin Cancer Res. 2019 02 15; 25(4):1216-1225.
Score: 0,150
-
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur J Cancer. 2016 11; 68:51-59.
Score: 0,129
-
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer. 2015 Jan; 51(1):18-26.
Score: 0,113
-
ASPECCT: panitumumab versus cetuximab for colorectal cancer--authors' reply. Lancet Oncol. 2014 Jul; 15(8):e303.
Score: 0,110
-
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May; 15(6):569-79.
Score: 0,109
-
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014 Jan; 50(2):320-31.
Score: 0,105
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12; 369(11):1023-34.
Score: 0,104
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 01; 30(28):3499-506.
Score: 0,097
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 01; 28(31):4697-705.
Score: 0,085
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 02; 360(14):1408-17.
Score: 0,077
-
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 2004 Jul 16; 4:36.
Score: 0,055
-
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 06; 11(3):383-400.
Score: 0,031